BioInvent Announces Publication of Data in Leading Cancer Journal Immunity
Retrieved on:
Tuesday, November 13, 2018
Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
Key Points:
- Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
- This research is the result of a long-standing collaborative effort between the Southampton Antibody and Vaccine Group, Centre for Cancer Immunology, BioInvent and Cancer Research UK, to promote translational research into effective cancer immunotherapies.
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.